FDA grants AP status for Lupin's Ramipril supplement
The FDA has granted approval status (AP) for Lupin's supplemental application for Ramipril under ANDA077626.
Asset / Drug
Drug and asset intelligence for Ramipril with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
ACE Inhibitor
No catalysts indexed for this entity yet.
July 13, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.